THE IMPACT OF NEUROPROTECTOR THERAPY, SOCIODEMOGRAPHY CHARACTERISTIC AND COMORBIDITIES ON HEALTH RELATED QUALITY OF LIFE (HRQOL) AND GCS SCORE IN STROKE INPATIENT OF GENERAL HOSPITAL CENTER DR. M. DJAMIL PADANG

• Main Author: Abdillah, Rahmad
• Format: Theses
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/78986
• Institution: Institut Teknologi Bandung

Stroke is the third most common cause of death worldwide. Health Related Quality ofLife (HRQoL) is a comprehensive assessment method to understand the disease burden of stroke patients. This study examined the impact of sociodemographic characteristics (gender, age, and occupation), type of neuroprotector, and comorbidity on HRQoL and Glasgow Coma Scale (GCS) in stroke patients. The research was conducted between January-March 2016. Total amount of 82 stroke patients were participated in this study. The patients were interviewed by using Stroke Specific Quality of Life (SSQoL) that have been translated to Indonesian. The sociodemographic data ofpatients were collected by interviewing the patients which were confirmed by their medical records. Data of stroke type and duration, comorbidities, and neuroprotector that was received by patients also obtainedfrom medical record. Statistical analysis t-test and one-way ANOVA were used to analyze the impact between sociodemographic characteristics, neuroprotector therapy and comorbidity of stroke patients to their HRQoL. Mann Whitney and Kurskal Wallis test were used to analyze the impact between sociodemographic characteristics, neuroprotector therapy and comorbidity of stroke patients to GCS. Analysis of univariance was used to analyze the impact of interaction among the type of comorbidities, dose ofneuroprotector, sociodemographic and otherfactor such as type of stroke and the recurrent of stroke to HRQoL and GCS. The 95% confidence intervals was considered to determine the significance. There was no significant impact between sociodemographic factors against HRQoL (p>0.1), but occupation significantly affected GCS (p<0.05). There was no significant impact between, dose variance ofciticoline neuroprotector, to HRQoL and GCS ofstroke patients (p>0,1). There was no significant impact between, comorbidity, on HRQoL of stroke patients (p<O.05), but on GCS it have significant impact (p<0.05). We found a significant impact ofinteraction among type ofstroke, dose variance ofciticoline, recurrent stroke, and comorbidity, on GCS (p<0.05)